Umbilical cord cells for diabetic foot wound healing

NewsBot · Feb 24, 2011

Members do not see these Ads. Sign Up.
Human Cord Blood-Derived Endothelial Progenitor Cells and Their Conditioned Media Exhibit Therapeutic Equivalence for Diabetic Wound Healing
Kim, Ji Yeon; Song, Sun-Hwa; Kim, Koung Li; Ko, Jeong-Jae; Im, Ji-Eun; Yie, Se Won; Ahn, Young Keun; Kim, Duk-Kyung; Suh, Wonhee
Cell Transplantation Volume 19, Number 12, 2010 pp. 1635-1644(10)

Transplantation of human cord blood-derived endothelial progenitor cells (EPCs) is reported to contribute to neovascularization in various ischemic diseases. However, the possible beneficial role and underlying mechanisms in diabetes-impaired wound healing have been less well characterized. In this study, EPC transplantation stimulated keratinocyte and fibroblast proliferation substantially as early as 3 days after injury, leading to significantly accelerated wound closure in streptozotocin-induced diabetic nude mice, compared to PBS control. RT-PCR analysis showed that EPCs secreted various wound healing-related growth factors. Among them, keratinocyte growth factor and platelet-derived growth factor were highly expressed in the EPCs and were present at substantial levels in the EPC-injected dermal tissue. Using EPC-conditioned medium (CM), we found that paracrine factors from EPCs directly exerted mitogenic and chemotactic effects on keratinocytes and fibroblasts. Moreover, injection of EPC-CM alone into the same diabetic wound mice promoted wound healing and increased neovascularization to a similar extent as achieved with EPC transplantation. These results indicate that the beneficial effect of EPC transplantation on diabetic wounds was mainly achieved by their direct paracrine action on keratinocytes, fibroblasts, and endothelial cells, rather than through their physical engraftment into host tissues (vasculogenesis). In addition, EPC-CM was shown to be therapeutically equivalent to EPCs, at least for the treatment of diabetic dermal wounds, suggesting that conditioned medium may serve as a novel therapeutic option that is free from allograft-associated immune rejection concern.
Click to expand...

NewsBot · May 11, 2020

One-year safety, healing and amputation rates of Wagner 3-4 diabetic foot ulcers treated with cryopreserved umbilical cord (TTAX01).
Marston WA et al
Wound Repair Regen. 2020 May 9

An open label, multicenter 16-week trial of cryopreserved human umbilical cord (TTAX01) was previously undertaken in 32 subjects presenting with a Wagner grade 3 or 4 diabetic foot ulcer, with 16 (50%) of these having confirmed closure following a median of one product application (previous study). All but two subjects (30/32; 94%) consented to participate in this follow-up study to 1-year postexposure. No restrictions were placed on treatments for open wounds. At 8-week intervals, subjects were evaluated for adverse events (AEs) and wound status (open or closed). Average time from initial exposure to end of follow-up was 378 days (range 343-433), with 29 of 30 (97%) subjects completing a full year. AEs were all typical for the population under study, and none were attributed to prior exposure to TTAX01. One previously healed wound re-opened, one previously unconfirmed closed wound remained healed, and nine new wound closures occurred, giving 25 of 29 (86.2%) healed in the ITT population. Three of the new closures followed the use of various tissue-based products. Three subjects whose wounds were healed required subsequent minor amputations due to osteomyelitis, one of which progressed to a major amputation (1/29; 3.4%). One additional subject underwent two minor amputations prior to healing. Overall, the study found TTAX01 to be safe in long-term follow-up and associated with both a low rate of major amputation and a higher than expected rates of healing.
Click to expand...

NewsBot · Oct 4, 2020

An open-label trial of cryopreserved human umbilical cord in the treatment of complex diabetic foot ulcers complicated by osteomyelitis
William A Marston et al
Wound Repair Regen. 2019 Nov;27(6):680-686

Clinical trials of potential new therapies for diabetic foot ulcers rarely enroll patients whose wounds extend to muscle, fascia, or bone with clinical and radiographic evidence of underlying osteomyelitis. An open-label, multicenter trial of cryopreserved human umbilical cord (TTAX01) was undertaken in 32 subjects presenting with such complex wounds with a mean duration of 6.1 ± 9.0 (range: 0.2-47.1) months and wound area at screening of 3.8 ± 2.9 (range: 1.0-9.6) cm2 . Aggressive surgical debridement at baseline resulted in 17 minor amputations and an increase in mean wound area to 7.4 ± 5.8 (range: 1.1-28.6) cm2 . All subjects were placed on systemic antibiotics for at least 6 weeks in conjunction with baseline application of TTAX01. Repeat applications were made at no less than 4-week intervals over the 16-week trial. Initial closure occurred in 18 of 32 (56%) wounds, with 16 (50%) of these having confirmed closure in 16 weeks with a median of one-product application. Cases with biopsy confirmed osteomyelitis (n = 20) showed initial closure in 12 (60%) wounds and confirmed closure in 10 (50%) wounds. Four of the five ulcers presenting as recurrences experienced confirmed closure. Mean overall time to healing was 12.8 ± 4.3 weeks. Mean wound area reduction from baseline was 91% for all wounds. Of the 16 wounds without confirmed closure during the 16-week treatment period, five (31.3%) achieved 99-100% wound area reduction by their final visit. The product was well tolerated. Two minor amputations occurred during the study period due to recurrent or persistent osteomyelitis; however, there were no major amputations.
Click to expand...

NewsBot · Sep 26, 2021

The role of the cord blood platelet gel in the management of a diabetic foot with tendon exposure
Mafalda Massara et al
Regen Med. 2021 Sep 24

Diabetic foot infection is frequent in diabetic patients and is due to neuropathy, trauma or peripheral arterial disease. The presence of an abscess requires urgent drainage and specific antibiotic therapy. Patients with critical limb ischemia need revascularization and, subsequently the intervention of a plastic surgeon is often required in cases of exposure of tendons and ligaments. During the COVID-19 pandemic, a patient was refered to our department with an abscess on the dorsum of the left foot. After urgent drainage with tendon exposure, he started specific antibiotic therapy and underwent tibial vessels angioplasty. After infection healing cord blood platelet gel was applied, accelerating the healing process, with injection of its liquid part into the exposed tendons, thus keeping the vital functions of the tendons.
Click to expand...

NewsBot · Oct 18, 2022

Expandable dehydrated human umbilical cord allograft for the management of nonhealing lower extremity wounds in patients with diabetes: a case series
Matthew Garoufalis, William Tettelbach
Wounds. 2022 Sep;34(9):E91-E95.

Advanced wound treatments are derived primarily from human placental membranes or animal tissue sources and composed of cellular and acellular dermal substitutes. The use of advanced wound treatments is practitioner directed and individualized to the wound characteristics. A multidisciplinary approach to wound closure is necessary, including the use of advanced treatments (eg, human umbilical cord derivatives) to achieve durable resolution of hard-to-heal wounds. In this case series, DHUC was used as an alternative to amniotic and amnion/chorion allografts for closure of a deep heel ulcer and a wound of the plantar aspect of the foot. The allografts were applied after wound closure had stalled with previous treatment attempts, which demonstrates use of DHUC in a staged approach to wound bed preparation and closure. The thickness and durability of DHUC allowed it to be used more like a skin graft for deep wounds. The meshed product can be expanded to provide a cost-effective solution to cover larger wound surfaces. It can be applied in an outpatient setting, thus avoiding more invasive and costly procedures (eg, split-thickness skin grafts). The use of umbilical allografts in the current report resulted in closure of stalled wounds and avoided hospitalization, thus reducing overall costs.
Click to expand...

Umbilical cord cells for diabetic foot wound healing

NewsBot The Admin that posts the news.

NewsBot The Admin that posts the news.

NewsBot The Admin that posts the news.

NewsBot The Admin that posts the news.

NewsBot The Admin that posts the news.

AMNIOX (cryopreserved human umbilical cord tissue) for plantar fasciitis

Spinal Cord Electrical Stimulator Implantation for Diabetic Foot Ulcers

Spinal cord stimulation for foot pain

Record keeping and domiciliary visits.

Patient records

Recording the effect of Covid-19 on podiatric practice

Clinic Records

Share This Page

Umbilical cord cells for diabetic foot wound healing

NewsBot The Admin that posts the news.

NewsBot The Admin that posts the news.

NewsBot The Admin that posts the news.

NewsBot The Admin that posts the news.

NewsBot The Admin that posts the news.

AMNIOX (cryopreserved human umbilical cord tissue) for plantar fasciitis

Spinal Cord Electrical Stimulator Implantation for Diabetic Foot Ulcers

Spinal cord stimulation for foot pain

Record keeping and domiciliary visits.

Patient records

Recording the effect of Covid-19 on podiatric practice

Clinic Records

Share This Page

Useful Searches